Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 26.07% | 7.74% | 35.52% | 42.83% | 47.86% |
| Total Depreciation and Amortization | -20.24% | -3.26% | -17.41% | -10.80% | -10.14% |
| Total Amortization of Deferred Charges | 0.00% | -35.23% | -8.51% | -4.44% | 29.32% |
| Total Other Non-Cash Items | -24.99% | -23.65% | -39.82% | -49.69% | -56.80% |
| Change in Net Operating Assets | -271.60% | 68.60% | 47.52% | 51.50% | 64.41% |
| Cash from Operations | -0.70% | 28.38% | 41.02% | 46.47% | 50.50% |
| Capital Expenditure | 69.32% | 87.50% | 96.89% | 87.74% | 59.12% |
| Sale of Property, Plant, and Equipment | 907.02% | -11.42% | -11.42% | -11.42% | -97.18% |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 133.99% | 124.19% | 90.82% | -4,711.39% | -11,730.29% |
| Cash from Investing | 130.19% | 119.77% | 92.58% | -286.09% | -263.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 91.73% | 90.40% | 79.51% | 60.54% | 47.43% |
| Issuance of Common Stock | 219.35% | -- | 138,964.29% | 23,077.38% | 10,427.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -403.38% | -616.98% | -339.34% | -44.71% | 71.16% |
| Cash from Financing | 229.97% | 3,650.87% | 1,731.52% | 1,122.14% | 534.96% |
| Foreign Exchange rate Adjustments | -182.86% | -195.39% | 96.00% | 171.53% | 364.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.88% | 84.87% | 68.65% | -2.48% | -16.51% |